Jay Galeota, Kallyope CEO
February 27, 2025 06:11 AM ESTUpdated 06:25 AM
Startups
R&D

Kally­ope qui­et­ly re­ports Phase 2 obe­si­ty da­ta, be­gins mid-stage mi­graine tri­al

Kyle LaHucik

Senior Reporter

Elizabeth Cairns

Senior biopharma journalist

Kally­ope, a New York City biotech that has raised about $480 mil­lion over the past decade, qui­et­ly

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B

A service from the Financial Times